M&A / Deals Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout Pharmaceutical TechnologyIf approved, Perfuse's PER-001 could continue Bayer's ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.OphthalmologyRead full story pharminent May 6, 2026 (Last updated: May 6, 2026) Pharmaceutical Technology If approved, Perfuse’s PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea. Ophthalmology Read full story Post navigation Previous: Lilly inflates US facility investment spending by $4.5bnNext: Novo hikes guidance on Wegovy pill’s fast sales start Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
